Daiichi Sankyo expands its OTC reach; Mylan to prohibit sales of drug for executions;

@FiercePharma: MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto. FiercePharmaMarketing story | Follow @CarlyHFierce

> Daiichi Sankyo has acquired ImCo, a growing mail-order OTC drug and cosmetics maker. Report

> Mylan ($MYL), bending to pressure, has agreed like many other drugmakers to write contracts that prevent distributors from selling its drug rocuronium bromide for use in lethal injections. Story

> The maker of the first liquid dose aspirin is looking for a partner. Report

> French vaccine maker Abivax is conducting clinical trials on a hepatitis C vaccined developed in Cuba. Story

Medical Device News

@FierceMedDev: Illumina expands in China with cancer Dx deal. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: U.K. patient group demands government override Roche's Kadcyla patents. Article | Follow @EmilyWFierce

> Google sees independent startups as key to new Alphabet reorganization. Report

> NIH's BRAIN initiative, philanthropic Kavli Foundation provide $185M to study brain science. More

> Siemens nabs Abbott SVP to run healthcare in North America. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Today's the FDA decision deadline for Keytruda's lung cancer app. Can't wait to see the TV ad. | Follow @DamianFierce

> XenoPort hits reset after a psoriasis setback, cutting jobs and bailing on R&D. Report

> Regeneron inks a $325M deal, selling Asian rights to a pain treatment. Story

> Sanofi steps deeper into RNAi work, opts in on Alnylam hemophilia drug. Article